Last updated: July 25, 2026
Executive summary: The record for case FWK Holdings, LLC v. Bausch Health Companies Inc., No. 3:19-cv-05426 is not present in the materials provided. Without the complaint’s asserted patents, the accused products, the litigation procedural history (motions, claim construction, trial/settlement/appeal), and the court’s substantive rulings, a complete and accurate litigation summary and analysis cannot be produced.
H1: FWK Holdings, LLC v. Bausch Health Companies Inc. 3:19-cv-05426 litigation summary and patent analysis
What patents are asserted in FWK Holdings v. Bausch Health (3:19-cv-05426)?
A litigation summary requires the asserted patent numbers (and the claim(s) alleged to be infringed). No patent-identifying information is included.
Which patent holders and assignees are involved?
Patent holder and assignment details must be pulled from the complaint, suit caption, and patent assignment data. No assignee data is provided.
What claims are alleged: composition, method-of-use, or manufacturing?
This depends on claim charts and the asserted independent claims in the complaint. No claim-level information is provided.
What products are accused of infringement in 3:19-cv-05426?
A correct infringement analysis requires identification of the accused Bausch Health product(s) and the dosage form(s) and strength(s) allegedly practiced. No accused-product details are provided.
Are the accused products a specific NDA/ANDA ANDA strength or a branded label?
This must be confirmed from the pleading and any exhibits. The record is not provided.
Are allegations directed to commercial sales, intended launch, or manufacturing process?
That depends on the complaint’s theory (literal infringement, doctrine of equivalents, inducement, and willful infringement). No pleading details are included.
What procedural posture does FWK Holdings v. Bausch Health reach?
A litigation timeline requires dates for service, responsive pleadings, claim construction, dispositive motions, trial events, and any appeal.
Key dates: complaint filed, answers, and motion deadlines
No docket events or calendar dates are provided.
Has the case been stayed, dismissed, or settled?
Settlement and stay outcomes must be sourced from docket entries. No docket record is included.
How does the court rule on infringement and validity in 3:19-cv-05426?
A “litigation analysis” must cite the court’s holdings on:
- claim construction
- infringement (direct/indirect/willfulness)
- invalidity (anticipation, obviousness, written description, enablement)
- inequitable conduct or prosecution history estoppel (if asserted)
No substantive rulings are included in the provided materials.
Did the court grant or deny summary judgment?
That requires order text or docket summaries. No order content is provided.
What is the status of injunction requests?
Injunction posture depends on the relief sought and the outcome of the merits. No relief details are provided.
Is this an ANDA/Paragraph IV-style case tied to Hatch-Waxman?
Most patent suits between NDA holders and ANDA filers map to Orange Book listings and Paragraph IV certifications. A determination requires:
- the drug’s FDA application type (NDA vs ANDA)
- the Orange Book patent listing(s) asserted
- the notice of certification (if relevant)
No drug/application identifiers or Orange Book context are provided.
Does FWK challenge patent certifications for a specific FDA application?
No FDA application number or certification details are provided.
What is the Orange Book status of the asserted patents?
Orange Book status requires specific listed patents and listing types (drug substance, drug product, method of use). No listing details are provided.
What Paragraph IV defenses and litigation strategies are used by Bausch Health?
A defensible analysis needs the asserted defenses and any Rule 12, summary judgment, or claim construction outcomes (noninfringement, invalidity, indefiniteness, prosecution history, lack of standing, improper venue, failure to state a claim).
No defenses or motions are available in the provided materials.
Are there damages-limit issues: design-around, nonwillfulness, or no continuous infringement?
Damages analysis requires the court record or settlement terms. No information is provided.
How strong is the FWK patent estate versus competing freedom-to-operate?
Strength scoring requires:
- which patents are asserted
- remaining term and expiry
- claim breadth and prosecution history
- prior art position and claim construction outcomes
- any co-pending suits or settlements
No patent numbers, priority dates, or outcomes are provided.
Patent expiration and exclusivity timing for the asserted estate
Timing analysis requires filing/priority and expiration data and any regulatory exclusivities. None is included.
Is there evidence of design-arounds by other filers?
That requires identifying competing generics/biosimilars and their FDA labels and litigation posture. No market comparators are provided.
Did the case end in settlement? What terms affect licensing or generic entry risk?
A settlement analysis depends on the settlement agreement terms (stay of litigation, scope of license, permitted generic launch date, and whether it includes covenant-not-to-sue).
No settlement terms or docket disposition are provided.
What launch dates or “trigger” dates exist post-settlement?
No settlement or trigger information is included.
Does the agreement create a license-in or covenant-not-to-sue for specific products?
No licensing scope details are provided.
Which court has jurisdiction and where is the case pending?
Jurisdiction and venue must be extracted from the caption and docket (district, division, presiding judge, and magistrate if any).
No court details are provided beyond the case number.
What is the assigned judge and has there been reassignment?
This requires docket access. No docket metadata is included.
How does this case compare with other FWK or Bausch Health patent litigations?
Comparisons require a set of related cases and outcomes (other dockets in the same family, coordinated cases, or parallel Hatch-Waxman litigations).
No related-case mapping is provided.
Key Takeaways
- A complete litigation summary and analysis for FWK Holdings, LLC v. Bausch Health Companies Inc., No. 3:19-cv-05426 cannot be generated from the information provided.
- The absence of asserted patent identities, accused products, procedural history, and court rulings prevents an accurate claims, validity, infringement, and exposure assessment.
FAQs
- What patents did FWK assert in 3:19-cv-05426, and what claims were targeted?
- Which Bausch Health product(s) were accused, by NDA/ANDA and strength?
- What motions (dismissal, summary judgment, claim construction) were decided in the case?
- Was the case stayed, settled, or appealed, and what was the disposition?
- Do the asserted patents map to Orange Book drug substance, drug product, or method-of-use listings?
References
- (No cited sources available from the provided materials.)
